CPHI Webinar Series - Pharma Action Against COVID-19 – Listen Now
Listen to recordings of all webinars broadcast during the week of May 04-08
Last week, CPHI ran a series of webinars providing expert insight and analysis on how pharma is responding to the COVID-19 pandemic in several key areas.
The five webinars offered quality content from industry leaders, focusing on important, cutting-edge topics such as the industry’s response to the COVID-19 pandemic, and the impact of the crisis on global supply chains, drug manufacturing, discovery and development.
If you missed any of the webinars, full recordings are available here.
Webinar 1: Response of Pharma to the COVID-19 Pandemic
Date: Monday, May 04, 2020
In our first webinar, we hear views and insights from senior consultants at Informa Pharma Intelligence, Duncan Emerton and Daniel Chancellor, alongside Pfizer CentreOne's Contract Manufacturing Business Leader, Tom Wilson on Pharma's ongoing response to the ongoing coronavirus pandemic.
Webinar 2: Drug Repurposing Trends – a CDMO perspective
Date: Tuesday, May 05, 2020
In this webinar, Anil Kane, Executive Director, Global Head of Technical & Scientific Affairs at Patheon, part of Thermo Fisher Scientific offers a CDMO’s perspective on the latest trends on the low-risk, cost effective drug repurposing strategy to redefine off-patent generics, clinical, shelved drugs or combination drugs to treat different indications and bring them faster to market.
Webinar 3: Managing the Changing Landscape: Building a Flexible, Challenge Resistant and Patient-Centric Clinical Supply Chain
Date: Wednesday, May 06, 2020
During this, the third in our webinar series, we hear from Nicole Gray and Stephen Flaherty, Strategic Supply Solutions at Catalent Pharma Solutions who explore strategies such as alternative supply models to improve supply chain efficiency, reduce risk and respond to local, regional and global challenges during this unprecedented global crisis.
Webinar 4: COVID-19: Impact on Cell and Gene Manufacturing
Date: Thursday, May 07, 2020
The cell and gene sector has exploded in the last few years, offering promising therapies for complex disease profiles for which there was previously no therapeutic solution. In this, the fourth installment of our webinar series, GenScript ProBio and Informa Pharma Intelligence tackle the impact of COVID-19 on the sector and touch on potential cell therapies for the treatment of COVID-19.
Webinar 5: Impact of COVID-19: AI and Machine Learning Solutions
Date: Friday, May 08, 2020
Rounding off our series of webinars, Dr. Yugal Sharma, Senior Director at CAS and Aurelio Arias, Engagement Manager, European Thought Leadership at IQVIA join forces to deliver the analysts’ view on how to optimise artificial intelligence and machine learning for predictive analytics, clinical trials and drug discovery.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...